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Summary
Insulin-like growth factors and their receptor (IGF-1R) have been implicated in cancer pathophysiology. We demonstrate
that IGF-1R is universally expressed in various hematologic (multiple myeloma, lymphoma, leukemia) and solid tumor
(breast, prostate, lung, colon, thyroid, renal, adrenal cancer, retinoblastoma, and sarcoma) cells. Specific IGF-1R inhibition
with neutralizing antibody, antagonistic peptide, or the selective kinase inhibitor NVP-ADW742 has in vitro activity against
diverse tumor cell types (particularly multiple myeloma), even those resistant to conventional therapies, and triggers
pleiotropic antiproliferative/proapoptotic molecular sequelae, delineated by global transcriptional and proteomic profiling.
NVP-ADW742 monotherapy or its combination with cytotoxic chemotherapy had significant antitumor activity in an or-
thotopic xenograft MM model, providing in vivo proof of principle for therapeutic use of selective IGF-1R inhibitors in
cancer.
Introduction cule inhibitors of IGF-1R function, but also to the fact that the
relative impact of inhibiting the IGF/IGF-1R pathway, compared
Insulin-like growth factors-1 (IGF-1) and -2 (IGF-2) have been to other cytokine/growth factor cascades, in tumor cell prolifera-
implicated in the pathophysiology of a wide range of human tion and survival have not been fully elucidated.
neoplasias due to the mitogenic and antiapoptotic properties Herein, we confirm in a broad panel of tumor types that
mediated by their type I receptor (IGF-1R or CD221) (reviewed IGF-1R is universally expressed and that multiple strategies for
in (LeRoith and Roberts, 2003). Expression of functional IGF-1R specific inhibition of IGF-1R function, including a selective small
molecule tyrosine kinase inhibitor, have potent antitumor effectsis required for neoplastic transformation in diverse tumorigene-
sis models (Werner and Le Roith, 1997). Until now, however, in vitro. Of the diverse tumor types studied, multiple myeloma
(MM) cell lines and primary tumor samples are particularly sensi-inhibition of the IGF-1R pathway had not been successfully
applied as a major anticancer therapeutic strategy. This has tive to IGF-1R inhibition, including cells with documented resis-
tance to various conventional or investigational anticancerbeen due not only to the lack of clinically applicable small mole-
S I G N I F I C A N C E
Epidemiological and experimental data have implicated the IGF/IGF-1R pathway in the establishment of human malignancies, but
this cascade has not been previously viewed as a major therapeutic target due to widespread IGF-1R expression in normal tissues
and a lack of clinically applicable small molecule inhibitors. Furthermore, while neutralizing monoclonal antibodies against human
IGF-1R have shown efficacy against xenograft tumors, a lack of reactivity against the host rodent receptor confounds assessment
of therapeutic index. This report validates IGF-1R as a therapeutic target for a broad spectrum of malignancies and provides in
vivo proof of concept for use of selective IGF-1R kinase inhibitors as primary antitumor therapy or in synergistic combination as
chemosensitizers. These results provide the rationale for clinical trials of small molecule IGF-1R inhibitors.
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drugs. Comprehensive transcriptional and proteomic analyses competitive peptide antagonist JB-1 (Hayry et al., 1995; Pietrz-
kowski et al., 1993), or the selective IGF-1R kinase inhibitorindicate that IGF-1R inhibition confers a pleiotropic constellation
NVP-ADW742 (Novartis Pharma AG, Basel, Switzerland). Cellu-of antiproliferative and proapoptotic molecular sequelae, which
lar kinase activity assays have demonstrated that NVP-ADW742provide a mechanistic explanation for the ability of IGF-1R inhibi-
has 16-fold more potent inhibitory effect against IGF-1R thantors to sensitize tumor cells to other anticancer drugs. IGF-1R
insulin receptor (InsR), the kinase with the highest homology toinhibition also blunts tumor cell response to other growth fac-
IGF-1R (IC50 0.17 and 2.8 M, respectively, in cellular autophos-tors, overcomes the drug resistance phenotype conferred by
phorylation assays; Supplemental Figure S2A). The selectivitythe bone microenvironment, and abrogates the production of
observed at the cellular level indicates that, despite the highproangiogenic cytokines. Importantly, in a clinically relevant
identity of the kinase domains of IGF-IR and InsR, there aremouse model of diffuse MM, systemic administration of the
differences between these receptors which can allow the selec-selective IGF-1R tyrosine kinase inhibitor NVP-ADW742 sup-
tive inhibition of IGF-1R, but not InsR. Furthermore, NVP-presses tumor growth, prolongs survival, and enhances the
ADW742 has much higher IC50 values for other kinases (e.g.,antitumor effect of cytotoxic chemotherapy. These studies pro-
IC50  10 M for HER2, PDGFR, VEGFR-2, or Bcr-Abl p210;vide proof of principle for IGF-1R kinase inhibition as a therapeu-
and IC50  5 M for c-Kit; Supplemental Figure S2A). Concor-tic strategy for a broad spectrum of malignancies, and elucidate
dant with these results, immunoblot analysis verified that NVP-previously unidentified aspects of the pathophysiology of IGF-
ADW742 blocks IGF-1-induced phosphorylation of IGF-1R and1R and its downstream molecular mediators. These results also
its known downstream target Akt (Mitsiades et al., 2002b) atprovide the rationale for the development of clinical therapeutic
submicromolar concentrations (Supplemental Figure S2B).strategies targeting IGF-1R.
All three anti-IGF-1R inhibitory strategies similarly sup-
pressed serum-stimulated increase of the total population ofResults
viable tumor cells in all cell lines tested (Figures 1A and 1B).
These results indicate that IGFs are key mediators of the abilityUniversal expression of IGF-1R in hematologic
of serum to stimulate the proliferation of tumor cells in vitro,malignancies and solid tumors
and that specific inhibition of IGF-1R function supercedes theWe used flow cytometry to study a panel of 75 hematologic
ability of other serum growth factors to stimulate proliferation/and solid tumor cell lines (Supplemental Table S1 at http://www.
growth. To determine if there were any cell type-specific differ-cancercell.org/cgi/content/full/5/3/221/DC1) for expression of
ences in response to IGF-1R inhibition, we assayed the effectIGF-1R using 2 different anti-human IGF-1R monoclonal anti-
of NVP-ADW742 on the viability of 58 hematologic and solidbodies. We found universal cell surface expression of IGF-1R
tumor cell lines. Dose-dependent inhibition of serum-inducedin all cell lines tested (representative examples shown in Supple-
cell growth was observed in all cell lines (Figure 1D). As a group,mental Figure S1), including hematologic malignancies (MM,
MM cell lines appeared to be more sensitive to the effects ofvarious subtypes of leukemias and lymphomas), as well as solid
NVP-ADW742, with IC50 values generally in the 0.1–0.5 Mtumors (prostate, breast, lung, colon, thyroid, ovarian, renal,
range, in comparison to the relatively higher IC50 values observedadrenal cancer, sarcomas, and retinoblastoma). To preclude
in most other hematologic and solid tumor cell lines.the possibility that IGF-1R expression is an artifact induced by
Focusing on MM, we evaluated the effect of IGF-1R inhibi-in vitro propagation, we also examined 35 freshly isolated pri-
tion on the viability of MM cells purified from primary patientmary MM tumor specimens, including samples from patients
samples in short-term culture assays immediately after isolation.with resistance to conventional or high-dose chemotherapy,
In all primary patient samples tested, inhibition of IGF-1R with
as well as classes of antitumor agents recently added to the
a neutralizing antibody or NVP-ADW742 completely suppressed
therapeutic armamentarium against MM, including thalidomide, serum-induced growth (Figure 1C and Supplemental Table S2).
its immunomodulatory analogs (CC-5013), and the proteasome As a specificity control, an anti-IL-6 receptor (IL-6R) neutralizing
inhibitor bortezomib (PS-341). Cell surface expression of IGF-1R antibody had no discernable effects on the viability of serum-
was also universally present in these primary patient samples cultured MM cells (Figures 1A and 1C and Supplemental Table
(representative examples shown in Supplemental Figure S1). S2). This finding may appear counterintuitive to the widely ac-
There was no discernible pattern of association between the cepted role of IL-6 in tumor cell proliferation, survival, and drug
degree of surface IGF-1R expression and tumor type, histologic resistance in MM (Anderson and Lust, 1999; Burger et al., 2001;
subtype, or resistance to anticancer drugs (e.g., alkylating Hallek et al., 1998) and other diseases, e.g., prostate cancer
agents, anthracyclines, dexamethasone, thalidomide, CC-5013, (Culig et al., 2002; Giri et al., 2001), raising the possibility that
TRAIL/Apo2L, or PS-341). serum concentrations of IL-6 are not sufficient to stimulate tu-
mor cells. However, we further found that the response of MM
In vitro antitumor activity of IGF-1R inhibitors and prostate cancer cells to exogenous administration of IL-6
The functional impact of specific inhibition of IGF-1R activation at levels in the 1–10 ng/ml range, which are 2–3 logs higher
in tumor cells was quantified in vitro by MTT colorimetric survival than serum levels (Nakashima et al., 2000), was also abrogated
assays, to evaluate the degree to which inhibition of IGF-1R by inhibition of IGF-1R (Figure 2). These findings underscore an
function can suppress the ability of serum (which contains IGFs) apparent pivotal role for IGF-1R function in the hierarchy of
to stimulate increase of the population of viable tumor cells. growth factor receptor systems in tumor cells.
These assays involved use of 10% or 20% fetal bovine serum Importantly, NVP-ADW742, -IR3 or JB-1 were active even
and/or pooled sera from healthy donors or sera from MM pa- against MM cell lines with known resistance to conventional
tients, in comparison with serum-free conditions. Specific inhibi- (cytotoxic chemotherapy, dexamethasone) or investigational
tion of IGF-1R function was achieved through use of a neutraliz- (thalidomide, CC-5013, TRAIL/Apo2L, PS-341) anticancer agents
(Figure 1), as well as primary tumor cells from MM patients withing monoclonal antibody -IR3 (Flier et al., 1986), the IGF-1-like
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Figure 1. In vitro antitumor activity of selective
IGF-1R inhibitions
A: In vitro antitumor activity of the IGF-1R inhibi-
tors NVP-ADW742 (0.5 M), -IR3 (2 g/ml), and
JB-1 (2 g/ml) against the dexamethasone-resis-
tant MM-1R cell line. Cells were incubated with
the indicated IGF-1R inhibitors or an IL-6R neu-
tralizing antibody (10 g/ml) for 2 days in the
presence or absence of serum. Results (mean 
SD) are expressed relative to the respective con-
trol (DMSO, mouse IgG1 antibody, or scrambled
peptide) and are representative of three inde-
pendent experiments performed in triplicate for
each experimental condition.
B: Comparative results of the effect of -IR3 2
g/ml or NVP-ADW742 0.5M for 72 hr on a panel
of drug-sensitive and resistant MM cell lines, as
well as prostate, breast, and thyroid carcinoma
cell lines (see Supplemental Table S1 at http://
www.cancercell.org/cgi/content/ful l/5/3/
221/DC1). Results (mean  SD) are presented as
the % suppression of serum-induced increase in
cell number and are representative of three in-
dependent experiments performed in triplicate
for each experimental condition.
C: Representative in vitro activity of -IR3, NVP-
ADW742, and anti-IL-6R (concentrations as spec-
ified in A) against primary MM tumor cells isolated
from a patient resistant to multiple conventional
and novel anti-MM therapies (thalidomide, CC-
5013, and PS-341). Results (mean  SD) are ex-
pressed relative to serum-free control and are
representative of two separate experiments per-
formed in duplicate for each experimental con-
dition.
D: Dose-response matrix of a panel of cell lines
from MM (black letters), other hematologic ma-
lignancies (red letters), and solid tumors (blue
letters) to NVP-ADW742 at 0–10M for 72 hr. Rela-
tive survival is visualized in an assigned color
scale. Results represent the mean for at least 2
independent experiments for each cell line, per-
formed in triplicate for each experimental con-
dition.
multi-drug-resistant disease (Supplemental Table S2). Further- in a mouse xenograft model of MM. Given the importance of
more, the degree of sensitivity of MM or other neoplasias to the tumor microenvironment in the biology of MM, we wished
IGF-1R inhibitors was not associated with the level of surface to establish an orthotopic MM model of bone and bone marrow
expression of IGF-1R (Supplemental Figure S1 and data not disease. The MM cell line MM-1S was engineered to stably
shown). Because the IGF/IGF-1R cascade can be counteracted express firefly luciferase fused to a selectable marker (neomycin
by the expression of IGF-receptor 2 (IGF-2R, IGF-IIR, CD222, phosphotransferase or enhanced GFP). Sublethally irradiated
or CIMPR; reviewed in LeRoith, 1996), we also studied the NOD/SCID mice were injected intravenously with MM-1S-Luc
expression of IGF-2R in our panel of tumor cells. We found that cells and tumor distribution was followed by serial whole-body
IGF-2R is expressed on the surface of a minority of tumor cell noninvasive imaging of visible light emitted by luciferase-express-
lines, but is found intracellularly in the entire tumor cell panel ing tumor cells upon injection of mice with luciferin (Armstrong
tested (Supplemental Figure S3). Again, we observed no dis- et al., 2003). Pilot experiments demonstrated that i.v. injections
cernible association between the degree of either surface or of MM-1S-Luc cells led to their engraftment to bone marrow and
intracellular IGF-2R expression and tumor type, histologic sub- bone and consistent establishment of multifocal bone lesions in
type, or resistance to the aforementioned panel of conventional
the axial skeleton (vertebrae, skull, pelvis) and long bones (Fig-and investigational anticancer drugs. Furthermore, there was
ure 3A and data not shown). The anatomic distribution of theseno apparent association between IGF-2R levels and sensitivity
MM lesions was consistent with the presentation of disease into IGF-1R inhibition.
human MM patients (Healy and Armstrong, 1998).
We evaluated the in vivo antitumor efficacy of IGF-1R inhibi-In vivo antitumor activity of the selective IGF-1R kinase
tion with NVP-ADW742 in our orthotopic MM model. Cohortsinhibitor NVP-ADW742
of mice with similarly increasing tumor burden were divided intoFocusing on MM as a model of IGF-1R-dependent neoplasias,
we evaluated the in vivo antitumor activity of IGF-1R inhibition control and treatment groups 3 weeks after tumor cell injection.
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Figure 2. IGF-1R inhibition abrogates the responsiveness of tumor cells to IL-6
In the presence of serum, the INA-6 MM cells (A) and PC-3 prostate cancer
cells (B) are responsive to IL-6 at the indicated concentration as shown by
MTT assays after 72 hr of incubation (solid symbols and lines). However, this
responsiveness is abrogated in the absence of serum (gray symbols and
line) or upon cotreatment with 0.5 M NVP-ADW742 (open symbols, dashed
lines). Results are presented relative to control cultures in serum only, and
represent the mean  SD of triplicate samples.
In this model of MM, NVP-ADW742 monotherapy (10 mg/kg
Figure 3. In vivo antitumor activity of the selective IGF-1R kinase inhibitor
i.p. twice daily) significantly suppressed tumor growth (Figure NVP-ADW742
3B) and prolonged the survival of mice (Figure 3C). There was A: Representative in vivo bioluminescence imaging of SCID/NOD mice in-
no difference in body weight between treatment groups (p  jected i.v. with 5  106 MM-1S-Luc human MM cells. Imaging 3 weeks after
0.82) and no other significant treatment-related toxicity dis- injection of cells reveals lesions in the spine, skull, and pelvis, with eventual
progression to diffuse disease. Quantification of total tumor burden (B) andcernable by necropsy and histopathological evaluation (data
Kaplan-Meier survival curve (C) of MM-1S-Luc orthografted mice receivingnot shown). Consistent results were obtained with a second
NVP-ADW742 (10 mg/kg i.p. twice daily) versus vehicle-treated control mice.
study with the same i.p. dosing, as well as a third study utilizing Homogeneous cohorts of mice with established tumor lesions were divided
NVP-ADW742 dosed orally at 50 mg/kg twice daily (data not into treatment groups, 3 weeks after injection of MM-1S-Luc cells. Treat-
ments were administered daily for 19 days. Relative bioluminescence isshown).
represented as mean  SD, n  6 per treatment group. Median survival of
mice treated 19 days with NVP-ADW742 was 38 days, in comparison to 21Molecular sequelae of IGF-1R inhibition days for control mice (p  0.02, log rank test).
To investigate the molecular pathways implicated in IGF-1R
activation and, conversely, its inhibition, we characterized the
molecular sequelae triggered in MM cells upon their exposure
to IGF-1R inhibitors (in the presence or absence of serum), using exposed cells were treated with either -IR3 or NVP-ADW742,
the expression profiles clustered with those of cells grown ingene expression profiling and signal transduction proteomic
profiling using multiplex immunoblotting analyses, as previously serum-free conditions as shown by unsupervised hierarchical
clustering (Figure 4A). Taken together, these results demon-described (Mitsiades et al., 2003a, 2003c). The functional sig-
nificance of findings detected in the global molecular profiling strate that activation of IGF-1R by the IGFs contained in serum
constitute a major part of the transcriptional effects of serum.assays was subsequently confirmed by specific mechanistic
assays. Furthermore, the global effects of inhibiting IGF-1R by NVP-
ADW742 or a specific neutralizing antibody are concordant,Global expression profiling revealed distinct transcriptional
profiles distinguishing serum-free from serum-stimulated cells thus further supporting the specificity of NVP-ADW742 activity.
Of note, unsupervised hierarchical clustering analyses(Figure 4A). Cells treated solely with physiological levels of IGF-1
(but otherwise serum-free) had expression profiles consistent showed that the gene expression profiles of MM cells treated
with IGF-1R inhibitor (NVP-ADW742 and -IR3) correspondedwith those of cells exposed to serum. Conversely, when serum-
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Figure 5. Effects of IGF-1R inhibition on proteasome, telomerase, NF-B, and
HIF-1 activities
MM-1S cells were grown for 24 hr in the absence (serum-free) or presence
of 10% fetal bovine serum (10% FBS), IGF-1 (200 ng/ml), IR3 (2 g/ml), NVP-
ADW742 (0.5 M), or anti-IL-6R antibody (2 g/ml).
20S proteasome activity (A), telomerase activity (B), NF-B DNA binding
activity (C), and HIF-1 DNA binding activity (D) were assayed and repre-
sented as mean  SD of duplicate samples.
constellation of proliferative/antiapoptotic molecular events,Figure 4. Molecular profiling of IGF-1R inhibition in myeloma cells
which were suppressed by IGF-1R inhibition with NVP-ADW742
A: Unsupervised hierarchical clustering of transcriptional profiles of MM-1S
or -IR3 (Figures 4–6)., The mechanistic implications of IGF-1Rcells cultured for the indicated times in the presence or absence of 10%
inhibition-induced transcriptional changes are comprehensivelyfetal bovine serum, NVP-ADW742 0.5M, -IR3 2g/ml, or IGF-1 200 ng/ml. In
this diagram, rows represent individual samples grown under the indicated analyzed in a separate study (C.S.M. et al., unpublished data).
conditions, while columns represent transcripts which are differentially ex-
pressed in the various samples of this analysis. The expression of transcripts
for each sample is visually represented as red for upregulated genes and
green for downregulated genes, according to a logarithmic color scale
(	3.0 corresponds to 3-log reduction and 3.0 to a 3-log increase in gene
expression) shown at the bottom of the gene expression profile matrix. The
branches of the dendrogram which appears on the right hand side of the
graph indicates that, based on their gene expression profiles, the samples
of this analysis can be separated in 2 main clusters, one corresponding to
IGF-1- or serum-treated samples and the other representing samples cul-
tured with IGF-1R inhibitors (NVP-ADW742 or IR-3) or cultured in serum-free
conditions.
B–C: Densitometric results of proteomic analyses of the signaling state of
MM-1S cells cultured in serum-containing medium in the presence or ab-
sence of NVP-ADW742 at 0.5 M. Results of phosphorylation state (B) and
total levels (C) of signaling mediators in the setting of NVP-ADW742 treat-
ment are represented as % of the respective controls (mean of 2 indepen-
dent replicates  SD). All differences were significant with p 
 0.05, except
where indicated (NS  not significant).
to a distinct cluster, separate from other clusters corresponding
to profiles of MM cells treated with other potent anti-MM agents
(including PS-341, hsp90 inhibitors and histone deacetylase Figure 6. Effects of IGF-1R inhibition on antiapoptotic signaling cascades
inhibitor; Mitsiades et al., 2002a, 2002c, 2003b). This suggests Confirmatory immunoblotting analyses indicate that upon NVP-ADW742
that the distinct molecular sequelae of IGF-1R inhibition do not treatment (0.5 M) of MM-1S cells in 10% FBS-containing medium, IGF-1R
inhibitor-induced cell death is preceded by pleiotropic antiproliferative/reflect a nonspecific cytotoxic or antiproliferative effect (data
proapoptotic molecular events, such as early suppression of Akt, MEK1/2,not shown).
and FKRHL-1 phosphorylation, as well as decrease in intracellular levels ofExpression profiling studies, proteomic analyses, and sub- Akt, Bmx, IKK-, and the osteoclastogenic stimulator (and mediator of bone
sequent confirmatory assays showed that tumor cell exposure resorption in osteolytic MM lesions) RANKL. No change in Bcl-2 levels is
apparent over the course of treatment.to IGF-1 or serum was associated with a highly pleiotropic
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Briefly summarized, IGF-1R inhibition led to decreased expres- caspase-dependent proapoptotic anticancer therapies includ-
ing dexamethasone, TRAIL/Apo2L, proteasome inhibitors, andsion of genes implicated in cell cycle progression/proliferation
and decreased Rb phosphorylation; decreased levels of cas- thalidomide analogs (Chauhan et al., 2001; Mitsiades et al.,
2002c, 2002d, 2002e, 2002f). Furthermore, NF-B activity andpase inhibitors (e.g., FLIP, XIAP, cIAP-2, survivin) and other
antiapoptotic regulators (e.g., A1/Bfl-1); suppression of multiple DNA damage repair genes play critical roles in tumor cell resis-
tance to cytotoxic chemotherapy (Mitsiades et al., 2003c; Wanggenes involved in DNA synthesis and DNA damage repair; sig-
nificant decrease in constitutive and serum-stimulation of telo- et al., 1999). In addition, proteasome function is a target of the
recently emerging small molecule inhibitor PS-341, also knownmerase activity; suppression of genes implicated in oncogenic
transformation (e.g., c-myb, DEK) and decreased phosphoryla- as bortezomib (Hideshima et al., 2001b; Mitsiades et al., 2002c,
2003c). Because inhibition of IGF-1R function attenuated all oftion (and total levels) of the Aurora family of kinases; decreased
expression of transcripts encoding the 26S proteasome sub- these pathways associated with cytoprotection and drug resis-
tance, we decided to evaluate whether IGF-1R inhibition canunits, modulation of other genes regulating proteasome function
(e.g., ubiquitin-specific proteases and ubiquitin conjugating en- enhance the antitumor activity of existing therapeutic strategies,
e.g., cytotoxic chemotherapy, dexamethasone, or proteasomezymes), and suppression of constitutive and serum-induced
activation of proteasome activity; decreased expression of inhibition. Furthermore, because the aforementioned antiapo-
ptotic pathways (which are suppressed by IGF-1R inhibition),genes for nucleocytoplasmic transport and other solute carrier
proteins regulating uptake of glucose and other metabolites; e.g., PI-3K/Akt, Ras/Raf/ERK1/2, IKK/NF-B, are also important
mediators of the protective effects of bone marrow stromalsuppression of heat shock proteins (e.g., hsp90); decreased
phosphorylation of critical kinases and kinase targets in the PI- elements on MM and other tumor cells from osteotropic neopla-
sias (Hideshima and Anderson, 2002; Mitsiades and Koutsilieris,3K/Akt pathway (including Akt, p70S6K, GSK3, FKHRL-1), Raf/
ERK1/2 pathway (MEK1/2), Src, STAT3, and FAK (focal adhe- 2001), we also decided to characterize the ability of IGF-1R
inhibitors to abrogate these tumor-stromal interactions.sion kinase); suppression of total intracellular levels of kinases
implicated in proliferative/antiapoptotic responses, including
Akt, p70S6K, Raf, Src, Bmx, IKK, and PDK1 (PI-3K-dependent IGF-1R inhibition sensitizes tumor cells to other
anticancer agentskinase); and suppression of transcriptional activity of NF-B and
HIF-1, 2 downstream targets of IKK and Akt, respectively. In vitro, we found that NVP-ADW742 or -IR3 could increase the
sensitivity of MM cells to various cytotoxic chemotherapeuticThe highly pleiotropic constellation of proliferative/antiapo-
ptotic pathways which are stimulated by serum and conversely agents (doxorubicin, melphalan), dexamethasone, TRAIL/Apo2L,
or PS-341 (Figures 7A–7C and Supplemental Figure S4 at http://inhibited by NVP-ADW742 may explain not only the potent
growth/survival signal mediated by IGF-1R in this study and in www.cancercell.org/cgi/content/full/5/3/221/DC1), the sensitiv-
ity of prostate cancer cells to doxorubicin, or the response ofprevious ones (Mitsiades et al., 2002b, 2002c; Poulaki et al.,
2002, 2003), but also the major impact of IGF-1R inhibitors on SK-N-MC sarcoma cells to Fas ligation (data not shown). These
data indicated a broader role of IGFs/IGF-1R signaling in attenu-a wide range of tumor types in this study. Several molecular
sequelae of IGF-1R inhibition elucidated by these studies are ating anticancer drug responsiveness in multiple neoplasias and
the potential usefulness of IGF-1R inhibitors in enhancing theconsistent with previously reported findings, e.g., those per-
taining to Akt, FKHRL-1, NF-B, and HIF-1 function or caspase antitumor activity of a broad spectrum of anticancer therapeutic
strategies.inhibitor expression (Mitsiades et al., 2002b, 2002c; Poulaki
et al., 2002, 2003). Other previously unidentified findings also Furthermore, the suppression of proteasome function by
IGF-1R inhibition provides first evidence of growth factor-medi-emerged. For example, IGF-1R inhibition appears to modulate
the signaling state of tumor cells not only by changes in phos- ated regulation of proteasome function. This finding offers a
mechanistic explanation for the demonstrated synergy betweenphorylation of the components of PI-3K/Akt, Ras/Raf/ERK1/2,
IKK/NF-B, or other signaling cascades, but also by modulating IGF-1R inhibition and PS-341 (Figure 7B), is consistent with our
previous observation that IGF-1-induced signaling attenuatesthe intracellular concentration of components of these path-
ways, including key kinases such as Akt, Raf, and IKK. Our MM cell sensitivity to PS-341 (Mitsiades et al., 2002c), and bears
major implications for the potential clinical applications offindings that IGF/IGF-1R signaling activates/upregulates several
signaling effectors (e.g., Akt, Raf, IKK) participating in signal IGF-1R inhibitors to enhance the antitumor activity of protea-
some inhibitors.transduction cascades triggered by other cytokines/growth fac-
tors and their receptors, and that the transcriptional profiles
of IGF-1R inhibitor treatment of serum-cultured MM cells are In vivo chemosensitizing effect of IGF-1R inhibition with
NVP-ADW742comparable to the profiles in serum-free conditions (Figure 4A),
highlight a critical role of IGF-1R function for the transcriptional Based on the in vitro chemosensitizing effect of NVP-ADW742
on tumor cells, we evaluated the in vivo activity of a pulseresponses of tumor cells to the entire spectrum of growth factors
present in serum. These results provide putative mechanistic of NVP-ADW742 (10 mg/kg i.p. twice daily, 4 days per week)
administered after low dose melphalan (2.5 mg i.p once a week).explanation for our prior finding that the biologic activity of IGFs/
IGF-1R may be required for priming of tumor cells to respond In contrast to continuous administration of NVP-ADW742, pul-
satile administration of NVP-ADW742 had no significant antitu-to other cytokines, which may not be sufficient per se to trigger
cell proliferation. mor activity (Figure 7D, and data not shown). However, consis-
tent with the in vitro data, the combination of subtherapeuticSeveral pathways abrogated by IGF-1R inhibition are critical
for tumor cell resistance to proapoptotic therapies and/or con- melphalan followed by subtherapeutic NVP-ADW742 had syner-
gistic effect in reducing tumor burden measured by in vivo im-stitute known targets for anticancer therapies. For example, Akt,
NF-B, and caspase inhibitors confer resistance to multiple aging (data not shown) as well as prolonging the survival of
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Figure 7. IGF-1R inhibition sensitizes tumor cells to other anticancer therapies
in vitro and in vivo
The in vitro anti-MM activities of dexamethasone (Dex 0.1 M, 72 hr, A)
and doxorubicin (Doxo, 50 ng/ml, 48 hr, B) are enhanced by NVP-ADW742
Figure 8. IGF-1R inhibition overcomes the protective effects conferred totreatment (0.75 M for the final 24 hr of incubation) in MM-1S cells.
MM tumor cells by their local bone microenvironmentC: IGF-1R inhibition (by -IR3 2 g/ml) enhances the activity of PS-341 (2 nM,
overnight incubation) against MM-1S cells. In all cases, cells were cultured in A: Unpurified bone marrow (BM) mononuclear cells from BM aspirate of
the presence of 10% FBS, and results are expressed as % of the viability of cells MM patient (which contain CD138 MM cells and CD138	 normal cells of
in the respective controls (cultures in serum-free conditions or supplemented the bone microenvironment, such as stromal cells) were cultured in the
with 10% serum, respectively) and correspond to the mean  SD of 3 inde- presence of 20% serum for 72 hr. NVP-ADW742 treatment (0.5 M) led to
pendent experiments. specific reduction in the percentage of the CD138population of malignant
D: In vivo combination therapy with NVP-ADW742. Two weeks after i.v. cells, but not BM stromal cells.
injection with MM-1S-Luc cells, a group of NOD-SCID mice with established B: NVP-ADW742 (0.5 M for 72 hr) does not significantly affect the viability
diffuse MM lesions was divided into 4 cohorts, with statistically equivalent of BM stromal cells (BMSCs) or normal peripheral blood B cells (PBL B cells),
tumor burden between cohorts (as assessed by bioluminescence imaging). in comparison to MM cell lines (MM-1S, MM-1R, MM-1S-Bcl-2).
Cohorts were treated with melphalan alone (2.5 mg/kg i.p. once a week), C: Coculture of primary MM cells with BMSCs for 24 hr triggers an increase
NVP-ADW742 alone (10 mg/kg i.p. twice daily, four days per week), melpha- in IGF-1 levels in the coculture supernatant.
lan followed 18 hr later by NVP-ADW742, or vehicle control. NVP-ADW742 D: IGF-1R inhibition by NVP-ADW742 (0.5M for 24 hr) suppresses the constitu-
enhanced the in vivo antitumor effect of melphalan, as shown by the tive and coculture-induced secretion of VEGF by myeloma cells and BMSCs.
prolongation of overall survival of mice receiving the combination of the 2 E: NVP-ADW742 (0.75 M) suppresses the IGF-1 (200 ng/ml in serum-free
agents (log-rank test, p  0.0008; n  5 per treatment group). medium)-induced secretion of VEGF by the SW579 papillary thyroid carci-
noma cells. All data are presented as the mean  SD of triplicate samples.
mice (Figure 7D). Taken together, these results demonstrate
nancies, such as MM, where stromal elements of the BM micro-that abrogation of IGF-1/IGF-1R signaling after cytotoxic ther-
environment confer protective effects to tumor cells againstapy may enhance the efficacy of conventional therapies by re-
various antitumor therapies (Hideshima and Anderson, 2002;moving key antiapoptotic signals.
Mitsiades and Koutsilieris, 2001). This protective effect may be
particularly relevant for strategies targeting IGF-1R, since IGFsImpact of IGF-1R inhibition on interactions of tumor
are locally produced in the BM milieu by BM stromal cellscells with the bone marrow microenvironment
(BMSCs) and osteoblasts, and because coculture of MM cellsand VEGF production
with BMSCs significantly enhances production of IGF-1 in vitroThe in vivo antitumor effects of IGF-1R inhibition may reflect
(Figure 8C). However, in coculture assays of MM cells andboth tumor cell-autonomous and -nonautonomous effects. The
BMSCs, their interaction did not overcome the antitumor effectsimportance of stromal elements in supporting tumor growth is
becoming increasingly clear, particularly in osteotropic malig- of NVP-ADW742 on MM cells (Figure 8A), even at concentrations
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which did not affect the viability of BMSCs (Figure 8B). Further- bcr-abl, c-kit, or PDGF receptor illustrated the concept of thera-
more, consistent with its ability to suppress IGF-1-induced peutic intervention with small-molecule kinase inhibitors which
HIF-1 activity, NVP-ADW742 decreased the production of neutralize single molecular targets that are mutationally acti-
VEGF by tumor cells and bone marrow stromal cells (Figure vated, uniquely expressed, or overexpressed in tumor versus
8D), and suppressed the IGF-1-induced secretion of VEGF by normal cells (Druker et al., 2001; Druker et al., 1996). Our current
various tumor types such as thyroid cancer cells (Figure 8E) or study presents a conceptually different therapeutic approach,
MM cells (data not shown), suggesting putative antiangiogenic because it focuses on a target which is expressed in a wide
effects of IGF-1R inhibition. These results not only suggest that range of neoplasias, but is not a pathognomonic neoplastic
IGF/IGF-1R signaling plays important roles in the interactions of alteration since it is also expressed in many, if not most, normal
tumor cells with their local microenvironment, including stromal tissues (LeRoith et al., 1995). However, our study shows that
protection of tumor cells or tumor-associated angiogenesis, IGF-1R inhibition not only has potent antitumor activity in vitro,
but also propose an additional mechanistic rationale for use of but also a favorable in vivo therapeutic window. These results
IGF-1R kinase inhibitors in order to maximize the in vivo efficacy suggest that IGF-1R function is critically required for tumor cell
of other antitumor therapies. survival, but dispensable for survival of normal cells in adult
animals. This highlights the notion that development of new
Discussion
anticancer therapeutic strategies, which traditionally focuses on
molecules with significant differential expression in tumor versusProspective epidemiological studies have indicated that high
normal cells, should also address molecular targets present inIGF-1 levels confer increased risk for development of diverse
both cell types, but with differential functional importance forsolid tumor types (Chan et al., 1998; Hankinson et al., 1998),
tumor cell survival and proliferation. Selective targeting of suchand prior studies have suggested a role for IGF-1R activation
nonpathognomonic pathways may also be associated with ain malignant transformation of certain tumor types (reviewed in
favorable therapeutic window. Furthermore, our finding that inhi-LeRoith and Roberts, 2003). However, less emphasis has been
bition of IGF-1R modulates responsiveness to other growthplaced on understanding how IGFs/IGF-1R influence the clinical
factors highlights a potential therapeutic application of IGF-1Rresponse of tumor cells to anticancer therapies, and only limited
kinase inhibitors to enhance response to therapeutic strategiesfocus has been placed on targeting the IGFs/IGF-1R pathway
targeting other growth factor/receptor signaling systems in tu-in the clinical setting (Koutsilieris et al., 2002). This study high-
mor cells.lights the potential utility of therapeutic targeting of IGF-1R func-
tion in cancer therapy. We demonstrate that IGFs in serum Because of the highly pleiotropic nature of the molecular
constitute critical promoters of tumor cell proliferation, survival, sequelae of IGF-1R and, conversely, its inhibition, the delinea-
and drug resistance in multiple neoplasias, and inhibition of tion of which one(s) of these effects is more important for the
IGF-1R significantly suppresses these effects. Global transcrip- biologic activity of IGF-1R or for the antitumor effect of its inhibi-
tional and proteomic profiling offers insight into the molecular tors is difficult, particularly because many of the downstream
sequelae of IGF-1R activation and inhibition, including modula- effectors of IGF-1R or its inhibition constitute per se targets
tion of a pleiotropic constellation of proliferative and antiapo- sufficient to trigger tumor cell death in vitro and in vivo, including
ptotic pathways. Finally, demonstration of in vivo efficacy of the ubiquitin/proteasome pathway (as evidenced by the clinical
systemic administration of a small molecule IGF-1R kinase in- activity of proteasome inhibitors; Richardson et al., 2003) and
hibitor establishes proof of principle that selective IGF-1R inhibi- the PI-3K/Akt, Raf/ERK1/2, and IKK/NF-B pathways (Hide-
tion can achieve in vivo antitumor activity with a favorable thera- shima et al., 2001a, 2002; Mitsiades et al., 2002b, 2002c, 2002e,
peutic window.
2003c; Wang et al., 1999). In fact, the pleiotropic molecular
Focusing on MM, the second most commonly diagnosed
effects of IGF-1R inhibition can explain not only its significanthematologic malignancy, as a disease critically dependent on
in vitro and in vivo antitumor activity, but also its ability to targetIGF-1R function, we demonstrated significant in vitro and in
such a wide range of tumor types from diverse lineages andvivo antitumor activity of the selective IGF-1R tyrosine kinase
significant differences in their molecular profiles. This wide spec-inhibitor NVP-ADW742 (both as a single agent, as well as in
trum of activity of IGF-1R inhibitors and, importantly, theircombination with cytotoxic chemotherapy), without significant
equally pleiotropic effects in selectively sensitizing tumor cellstreatment-related toxicity. NVP-ADW742 recapitulated the bio-
to a wide range of anticancer agents, not only highlight thelogic effects of anti-IGF-1R-specific neutralizing antibody or
major role of IGF/IGF-1R signaling for human malignant cells,inhibitory peptide, induced pleiotropic antiproliferative/proapo-
but also provide the framework for future clinical trials of specificptotic biologic sequelae in tumor cells, and was active even
tyrosine kinase inhibitors of IGF-1R to improve the outcome ofagainst primary tumor cells from patients with multi-drug-resis-
tant disease or tumor cell lines with known resistance to various patients with IGF-responsive malignancies.
conventional or investigational anticancer drugs. IGF-1R inhibi-
Experimental procedurestion attenuates tumor cell responsiveness to other cytokines/
growth factors, selectively increases tumor cell sensitivity to
Cell lines and primary tumor specimensother (conventional or novel) anticancer therapies, overcomes
Cell lines were obtained from the ATCC (Manassas, VA) or were kindly
the protective effect of bone marrow stromal cells, and abro-
provided by sources indicated in the Supplemental Experimental Procedures
gates the production of proangiogenic cytokines such as VEGF at http://www.cancercell.org/cgi/content/full/5/3/221/DC1. Primary MM pa-
by tumor and stromal cells. tient samples were freshly isolated from bone marrow aspirates from patients
The major clinical responses achieved by imatinib mesylate undergoing diagnostic or restaging bone marrow aspirates under an IRB-
approved protocol.(STI-571, Gleevec) against neoplasias critically dependent on
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Transfections and retroviral transductions was defined as the time between i.v. injection of tumor cells and sacrifice,
Stable transfections of MM-1S cells with vectors encoding myristoylated or death and was compared across different treatment groups with Kaplan-
(constitutively active) Akt or Bcl-2 (Upstate Biotechnologies, Lake Placid, Meier survival analysis (Kaplan and Meier, 1958).
NY), or with empty (neo) vectors, were performed using Lipofectamine 2000
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